Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a leading innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), has inaugurated Unit VI, a state-of-the-art facility for veterinary active pharmaceutical ingredient (API) production in Bidar, Karnataka. The announcement was made on September 18, 2025, in compliance with SEBI disclosure regulations.
The new Unit VI is located alongside the company’s flagship API manufacturing site, Unit IV, in Bidar. Built to meet global standards of safety, sustainability, and regulatory compliance, the facility is exclusively designed for veterinary applications. According to the company, this expansion will provide scalable and efficient manufacturing solutions to global animal health companies.
Commenting on the launch, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said the investment “strengthens our ability to meet the growing global demand for high-quality veterinary pharmaceuticals while ensuring innovation, efficiency, and sustainability.”
The company highlighted that the veterinary API market offers a strong growth opportunity, driven by rising demand for animal healthcare and veterinary medicines worldwide. With over two decades of manufacturing expertise, Sai Life Sciences said its new facility leverages advanced technologies, robust supply chain practices, and best-in-class safety standards to deliver reliable and cost-effective animal health APIs.
Sai Life Sciences works with over 300 global pharma and biotech companies and has operations across India, the UK, and the USA, with a workforce of more than 3,400 professionals.
